Download MendeleyNovel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model.
Wang, Y., Yu, L., Deng, K., Packiarajan, M., Aguilar, A., An, S., Liu, X., Myers, G., Oh, H., Singh, S.A., Cho, U.S., Wang, S., Guan, Y., White, A.D., Khoriaty, R., Engel, J.D.(2025) Blood 146: 356-368
- PubMed: 40332031
- DOI: https://doi.org/10.1182/blood.2024028006
- Primary Citation of Related Structures:
9DBP - PubMed Abstract:
Small molecules that inhibit LSD1 (lysine-specific demethylase 1, KDM1A) have been shown to induce abundant fetal hemoglobin (HbF) levels in red blood cells both in vitro and in vivo, therefore potentially serving as potent and cost-effective therapeutics to treat the β-globinopathies, sickle cell disease (SCD), and β-thalassemia major (TM). However, most LSD1 inhibitors (LSD1is) that induce HbF in vivo are covalent and irreversible, which leads to adverse effects. In this study, we utilized structure-aided drug design to develop potent new reversible LSD1is, leading to robust γ-globin expression in vitro. Moreover, in a mouse model of SCD, oral administration of these novel inhibitors leads to significant HbF elevation and alleviation of multiple features of disease pathology that are the usual consequences of SCD. In addition, we discovered that combined treatment of an LSD1i with a BRD4 degrader (BD-9136) represses the induction of RUNX1 and PU.1, thereby rescuing the erythroid to myeloid lineage conversion that accompanies LSD1is in hematopoiesis. The data indicate that this new generation of LSD1is can effectively induce HbF levels, reduce SCD pathologies, and are well tolerated by oral administration in SCD mice. We anticipate that the combination of these or related binary compounds offer exciting new therapeutic possibilities for treating SCD and TM.
- Department of Cell Biology, Medical School, University of Michigan, Ann Arbor, MI.
Organizational Affiliation:
